Therapy

John Huston's documentary for the U.S. Army about soldiers treated for psychiatric breakdown at Mason General Hospital on Long Island after the Second World War. The Army kept it from the public until 1980. Its scenes of narcosynthesis, in which doctors interview soldiers under an intravenous barbiturate, record a drug-assisted psychotherapy that came before the LSD era.

A memo from anthropologist [Margaret Mead](/biographies/margaret-mead)'s papers at the Library of Congress, recording her interest in LSD and other psychedelics in the summer of 1954 and her work with [Harold Abramson](/biographies/harold-abramson)'s research team, including [Conan Kornetsky](/biographies/conan-kornetsky) and [Murray Jarvik](/biographies/murray-jarvik).

The psychologist Betty Eisner (1915–2004) recalls being the first research subject in Sidney Cohen's LSD study at UCLA in October 1955, quoting at length from the report she wrote after the session. The excerpt describes the psychological tests she was asked to take while under the drug, and her sense that they were trivial beside what she was experiencing. It is the opening chapter of her unpublished memoir, Remembrances of LSD Therapy Past (2002).

A 1955 medical film made for the drug company Wm. S. Merrell about Howard D. Fabing's experiments at Christ Hospital in Cincinnati. A 22-year-old graduate student, "Ronnie," takes 100 micrograms of LSD; the film then shows Merrell's compound MER-17 (azacyclonol, sold as Frenquel) given to prevent or reverse the effects. It belongs to the 1950s search for drugs that could block a "model psychosis."

Foundations for a Combined Therapeutic Technique

Luisa G. de Álvarez de Toledo's paper to the Argentine Psychoanalytic Association in Buenos Aires on September 10, 1957, setting out a method for combining LSD sessions with psychoanalysis. Case reports by Alberto E. Fontana and Francisco Pérez Morales follow. It is one of the earliest attempts in Latin America to fit LSD into psychoanalytic treatment.

The transcript of the FDA advisory committee that reviewed Lykos Therapeutics' application for MDMA-assisted therapy for post-traumatic stress disorder. Hosted here are the chair's opening of the committee questions and the two votes: 2 to 9 against finding the drug effective, and 1 to 10 against finding that its benefits outweighed its risks, with each member's stated reasons. Members cited functional unblinding, expectation bias, the many trial participants who had used MDMA before, and reports of misconduct. The FDA declined to approve the application in August 2024.